Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) have earned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $46.2857.

Several brokerages have weighed in on ZBIO. HC Wainwright restated a “buy” rating on shares of Zenas BioPharma in a research report on Tuesday. Evercore ISI started coverage on Zenas BioPharma in a research note on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Monday, December 15th. Morgan Stanley boosted their target price on Zenas BioPharma from $34.00 to $37.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Finally, Wall Street Zen upgraded Zenas BioPharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th.

Zenas BioPharma Trading Up 3.1%

Shares of ZBIO stock opened at $36.15 on Tuesday. The business’s fifty day moving average price is $33.47 and its 200 day moving average price is $21.85. The firm has a market capitalization of $1.94 billion, a PE ratio of -5.11 and a beta of -1.61. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. Zenas BioPharma has a 1-year low of $5.83 and a 1-year high of $41.50.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, November 12th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.35).

Insider Activity

In other Zenas BioPharma news, Director Patrick G. Enright bought 105,265 shares of the business’s stock in a transaction on Thursday, October 9th. The stock was bought at an average price of $19.00 per share, for a total transaction of $2,000,035.00. Following the completion of the transaction, the director owned 1,832,669 shares in the company, valued at approximately $34,820,711. The trade was a 6.09% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Hongbo Lu purchased 263,160 shares of Zenas BioPharma stock in a transaction on Tuesday, October 7th. The stock was acquired at an average cost of $19.00 per share, for a total transaction of $5,000,040.00. Following the acquisition, the director directly owned 321,983 shares of the company’s stock, valued at approximately $6,117,677. This represents a 447.38% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 923,035 shares of company stock worth $17,628,163 in the last three months. Company insiders own 16.50% of the company’s stock.

Institutional Investors Weigh In On Zenas BioPharma

A number of large investors have recently bought and sold shares of ZBIO. Federated Hermes Inc. raised its holdings in shares of Zenas BioPharma by 60.8% in the second quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock worth $18,041,000 after acquiring an additional 703,838 shares during the last quarter. Vanguard Group Inc. increased its position in Zenas BioPharma by 17.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock worth $25,813,000 after purchasing an additional 170,546 shares in the last quarter. Geode Capital Management LLC raised its stake in Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after purchasing an additional 16,461 shares during the last quarter. Invesco Ltd. purchased a new position in Zenas BioPharma in the 3rd quarter valued at about $3,237,000. Finally, Millennium Management LLC purchased a new position in Zenas BioPharma in the 3rd quarter valued at about $1,595,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.